Ligand-Switchable Micellar Nanocarriers for Prolonging Circulation Time and Enhancing Targeting Efficiency

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Drug Delivery

Background:

• Targeted drug delivery using nanomedicines aims to enhance tumor accumulation and reduce chemotherapy side effects.
• Immune recognition of nanocarrier surface ligands shortens circulation time and impairs targeting efficiency.
• Current strategies face challenges with premature ligand exposure and immune system interactions.

Purpose of the Study:

• To develop a ligand-switchable micellar nanocarrier system for improved targeted drug delivery.
• To overcome the limitations of non-switchable nanocarriers regarding circulation time and tumor accumulation.
• To create a universal targeting strategy for nanomedicines.

Main Methods:

• Development of a micellar nanocarrier with ligands that can be hidden or exposed.
• In vivo evaluation of the nanocarrier's blood circulation half-life and tumor accumulation.
• Comparative analysis against nanocarriers with permanently exposed targeting ligands.

Main Results:

• The ligand-switchable nanocarrier exhibited a 66% longer blood circulation half-life.
• Tumor accumulation was increased by 23% compared to conventional nanocarriers.
• The ligand-switching mechanism effectively masked ligands in circulation and exposed them in the tumor microenvironment.

Conclusions:

• Ligand-switchable nanocarriers represent a significant advancement in targeted drug delivery.
• This strategy enhances pharmacokinetic profiles and tumor targeting efficacy.
• The developed system offers a universal approach to improve nanomedicine performance.